MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells

Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several mechanisms implicated in resistance have been identified, but the existence of multiple resistance mechanisms in parallel ha...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncogenesis
Huvudupphovsmän: Jakobsen, K R, Demuth, C, Madsen, A T, Hussmann, D, Vad-Nielsen, J, Nielsen, A L, Sorensen, B S
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2017
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520494/
https://ncbi.nlm.nih.gov/pubmed/28368392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2017.17
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk